1. Developmental origins of nonalcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease
   Frank T. Spradley et al, 2018, American Journal of Physiology-Endocrinology and Metabolism CrossRef
2. The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension
   Yuan Yuan et al, 2020, PLOS ONE CrossRef
3. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
   Amedeo Lonardo et al, 2018, Journal of Hepatology CrossRef
4. Immunomodulatory properties of antihypertensive drugs and digitalis glycosides
   Paweł Bryniarski et al, 2022, Expert Review of Cardiovascular Therapy CrossRef
5. Effects of hypertension and antihypertensive treatments on sulfatide levels in serum and its metabolism
   Ran Guo et al, 2019, Hypertension Research CrossRef
6. GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients
   Ernest A. Adeghate, 2024, Expert Opinion on Pharmacotherapy CrossRef
7. Ideal Cardiovascular Health Is Inversely Associated with Nonalcoholic Fatty Liver Disease: A Prospective Analysis
   Long Wang et al, 2018, The American Journal of Medicine CrossRef
8. Amlodipine, an anti‐hypertensive drug, alleviates non‐alcoholic fatty liver disease by modulating gut microbiota
   Yang Li et al, 2022, British Journal of Pharmacology CrossRef
9. Recent Advances in the Treatment of Insulin Resistance Targeting Molecular and Metabolic Pathways: Fighting a Losing Battle?
   Marta Wolosowicz et al, 2022, Medicina CrossRef